Announcement • May 14

+ 1 more update

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of 2seventy bio, Inc. (NasdaqGS:TSVT).

Bristol-Myers Squibb Company (NYSE:BMY) agreed to acquire 2seventy bio, Inc. (NasdaqGS:TSVT) for approximately $280 million on March 10, 2025. A cash consideration will be paid by Bristol-Myers Squibb Company at $5 per share. In case of termination of transaction, seller will pay a termination fee of $10 million. The transaction is subject to approval of merger agreement by target board, approval of offer by acquirer board, approval of offer by target shareholders, minimum tender and subject to antitrust regulations. The deal has been unanimously approved by the board. The transaction is expected to complete in Q2, 2025. On April 17, 2025, each of 2seventy bio and Bristol-Myers Squibb filed a Premerger Notification and Report Form under the HSR Act with the FTC and the Antitrust Division in connection with the Transactions. Under the HSR Act and the rules and regulations promulgated thereunder by the FTC, the waiting period applicable to the purchase of Shares pursuant to the Offer will expire on May 2, 2025, at 11:59 p.m., Eastern Time and 2seventy bio and Bristol-Myers Squibb have requested “early termination” of such waiting period. Goldman Sachs & Co. LLC acted as financial advisor for 2seventy bio, Inc. Michael H. Bison,Robert Masella,Gregg L. Katz,Mark S. Opper,Tevia K. Pollard,Shannyn Henke,Alexandra S. Denniston,Caroline H. Bullerjahn,Christina Ademola, Arman Oruc,Simone Waterbury,Sarah Jordan,Timothy Holahan,Chad E. Vella,Justin C. Pierce,Steven Tjoe,Roger A. Cohen,Julie Tibbets,Kevin D. Grumberg,Lindsay Thomas,Robert D. Carroll,Alicia Rubio-Spring,Daniel S. Karelitz and Brian H. Mukherjee of Goodwin Procter LLP acted as legal advisor for 2seventy bio, Inc. Catherine Dargan, Drew Fischer, Kyle Rabe,Ingrid Rechtin, Megan Woodford,Brady McDaniel, Winsome Cheung, Natalie Derzko,Marie Lavalleye,Mike Labson and Michael Stern of Covington & Burling LLP acted as legal advisor for Bristol-Myers Squibb Company. Goldman Sachs & Co. LLC acted as fairness opinion provider for 2seventy bio, Inc. Christopher Hanfling and Joe Goldman of Jones Day acted as tax counsel to Bristol Myers Squibb in the transaction. Gordon Dyal & Co. Advisory Group LP acted as financial advisor to Bristol-Myers Squibb Company (NYSE:BMY). Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of 2seventy bio, Inc. (NasdaqGS:TSVT) on May 13, 2025. 43.54 million shares of Bristol Common Stock were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 81.8% of the total number of shares of Bristol Common Stock outstanding at the Expiration Time.

2seventy bio, Inc. Stock Price

TSVT Share Price Performance

TSVT Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

2seventy bio, Inc. Key Details

About TSVT

Recent TSVT News & Updates

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of 2seventy bio, Inc. (NasdaqGS:TSVT).

2seventy bio, Inc.(NasdaqGS:TSVT) dropped from NASDAQ Biotechnology Index

Recent updates

2seventy bio, Inc. Competitors

CytomX Therapeutics

Cryoport

Nuvectis Pharma

MapLight Therapeutics